SLC9A5

Sodium/hydrogen exchanger 5 · Q14940 · SLC9A5 on Sugi Atlas →

1,770 patent compounds predicted against SLC9A5, 1,096 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2703175	0.54	11/20
SCHEMBL2432734	0.48	9/20
SCHEMBL829154	0.69	6/20
SCHEMBL1586403	0.69	6/20
SCHEMBL2054482	0.69	6/20
Iodide (SCHEMBL1587056)	0.67	6/20
SCHEMBL3530142	0.58	6/20
SCHEMBL2431417	0.49	6/20
SCHEMBL3864469	0.46	6/20
Amiloride (SCHEMBL27563)	1.00	5/20
Amiloride (SCHEMBL136682)	0.93	5/20
Amiloride (SCHEMBL871514)	0.90	5/20
SCHEMBL2690754	0.83	5/20
5-(N-Methyl-N-Isobutyl)Amiloride (SCHEMBL2432777)	0.45	5/20
SCHEMBL3121705	0.39	5/20
SCHEMBL3129941	0.37	5/20
Hydrochloric Acid (SCHEMBL2432725)	0.36	5/20
Hydrochloric Acid (SCHEMBL2432791)	0.36	5/20
5-(N-Methyl-N-Isobutyl)Amiloride (SCHEMBL2431320)	0.36	5/20
Amiloride (SCHEMBL4155066)	0.96	4/20

Clinical trials — most relevant to SLC9A5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study	PHASE4	RECRUITING
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure	PHASE4	RECRUITING
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis	EARLY_PHASE1	RECRUITING
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Disclosure of Genetic Risk for Salt Sensitivity	nan	UNKNOWN
Gene Expression in Inflammatory Bowel Disease	nan	ENROLLING_BY_INVITATION
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients	nan	UNKNOWN
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS	nan	COMPLETED
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Sodium Transport: Genetics and Hypertension	nan	COMPLETED
Blood Pressure Control in Juveniles - Longitudinal Study	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Adverse Airway Effects From Tobacco and E-Cigarettes	nan	UNKNOWN
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
New Biomarkers and Difficult-to-treat Hypertension	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease	nan	COMPLETED
Hereditary Tubulointerstitial Nephritis	nan	COMPLETED
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Healthy Humans.	nan	COMPLETED
Double Blind Crossover Comparison of Diuretics in the Young	nan	UNKNOWN
Clinical Utility of Breath Tests in GI	nan	COMPLETED
The Effects of Isotonic and Hypertonic Saline Infusion on Renal Biomarkers in Healthy Young Subjects	nan	COMPLETED
How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ Signals in Uterine Epithelial Cells	nan	COMPLETED
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC9A5 binder may also engage these)

Protein	Name	Similarity
B2RXE2	—	1.000	B2RXE2 →
Q9Z0X2	—	0.998	Q9Z0X2 →
SLC9A3	Sodium/hydrogen exchanger 3	0.998	landscape →
P26432	—	0.995	P26432 →
G3X939	—	0.993	G3X939 →
P26433	—	0.992	P26433 →
Q28362	—	0.989	Q28362 →
Q9Z0S8	—	0.988	Q9Z0S8 →
P16283	—	0.985	P16283 →
P04920	—	0.984	P04920 →
P23348	—	0.984	P23348 →
Q5RD44	—	0.984	Q5RD44 →
M5A7P9	—	0.982	M5A7P9 →
P23347	—	0.982	P23347 →
P48746	—	0.981	P48746 →
Q5RAQ1	—	0.981	Q5RAQ1 →
Q61762	—	0.981	Q61762 →
D3YWQ0	—	0.981	D3YWQ0 →
Q9JL58	—	0.981	Q9JL58 →
O60423	—	0.980	O60423 →
Q761V0	—	0.980	Q761V0 →
Q9MYV9	—	0.979	Q9MYV9 →
Q8CJI3	—	0.979	Q8CJI3 →
D3ZEY4	—	0.979	D3ZEY4 →
Q8K596	—	0.979	Q8K596 →
Q8K2X1	—	0.979	Q8K2X1 →
A5D7L5	—	0.979	A5D7L5 →
Q5RB85	—	0.979	Q5RB85 →
Q6SJP2	—	0.979	Q6SJP2 →
Q2KHU5	—	0.979	Q2KHU5 →